D.E. Shaw & Co
RARE icon

D.E. Shaw & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

D.E. Shaw & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Buy
1,261,018
+916,255
+266% +$20.6M 0.02% 983
2025
Q4 		$7.93M Buy
344,763
+107,123
+45% +$3.52M ﹤0.01% 1945
2025
Q3 		$7.15M Sell
237,640
-303,161
-56% -$9.09M ﹤0.01% 1927
2025
Q2 		$19.7M Sell
540,801
-15,616
-3% -$563K 0.01% 1046
2025
Q1 		$20.1M Buy
556,417
+270,338
+94% +$11.2M 0.02% 940
2024
Q4 		$12M Buy
286,079
+24,485
+9% +$1.21M 0.01% 1376
2024
Q3 		$14.5M Buy
261,594
+58,152
+29% +$2.96M 0.01% 1189
2024
Q2 		$8.36M Buy
+203,442
New +$8.69M 0.01% 1446
2023
Q4 		– Sell
-6,152
Closed -$219K – 4554
2023
Q3 		$219K Sell
6,152
-88,777
-94% -$3.52M ﹤0.01% 3729
2023
Q2 		$4.38M Sell
94,929
-25,959
-21% -$1.2M ﹤0.01% 1961
2023
Q1 		$4.85M Sell
120,888
-169,107
-58% -$7.26M 0.01% 1955
2022
Q4 		$13.4M Sell
289,995
-182,359
-39% -$7.17M 0.01% 1186
2022
Q3 		$19.6M Buy
472,354
+112,837
+31% +$5.8M 0.02% 859
2022
Q2 		$21.4M Sell
359,517
-124,821
-26% -$7.68M 0.03% 817
2022
Q1 		$35.2M Sell
484,338
-62,253
-11% -$4.33M 0.03% 665
2021
Q4 		$46M Buy
546,591
+70,884
+15% +$5.77M 0.04% 597
2021
Q3 		$42.9M Sell
475,707
-290,390
-38% -$26.2M 0.04% 603
2021
Q2 		$73M Buy
766,097
+14,929
+2% +$1.56M 0.06% 377
2021
Q1 		$85.5M Buy
751,168
+35,881
+5% +$4.88M 0.08% 284
2020
Q4 		$99M Buy
715,287
+284,395
+66% +$33.7M 0.09% 270
2020
Q3 		$35.4M Buy
430,892
+93,728
+28% +$7.77M 0.04% 555
2020
Q2 		$26.4M Sell
337,164
-61,310
-15% -$4.06M 0.03% 640
2020
Q1 		$17.7M Buy
398,474
+84,306
+27% +$4.38M 0.03% 688
2019
Q4 		$13.4M Buy
314,168
+125,785
+67% +$5.19M 0.02% 1035
2019
Q3 		$8.06M Buy
188,383
+54,777
+41% +$2.98M 0.01% 1313
2019
Q2 		$8.48M Sell
133,606
-10,571
-7% -$673K 0.01% 1228
2019
Q1 		$10M Sell
144,177
-177,657
-55% -$10.2M 0.01% 1101
2018
Q4 		$14M Buy
321,834
+316,434
+5,860% +$17.3M 0.02% 888
2018
Q3 		$412K Buy
+5,400
New +$439K ﹤0.01% 3213
2017
Q4 		– Sell
-12,682
Closed -$675K – 3707
2017
Q3 		$675K Sell
12,682
-54,193
-81% -$3.21M ﹤0.01% 2740
2017
Q2 		$4.15M Buy
66,875
+29,212
+78% +$1.76M 0.01% 1488
2017
Q1 		$2.55M Buy
+37,663
New +$2.87M ﹤0.01% 1685
2016
Q1 		– Sell
-58,488
Closed -$6.56M – 3716
2015
Q4 		$6.56M Buy
58,488
+47,790
+447% +$4.78M 0.01% 1226
2015
Q3 		$1.03M Buy
10,698
+5,398
+102% +$618K ﹤0.01% 2594
2015
Q2 		$543K Sell
5,300
-21,428
-80% -$1.66M ﹤0.01% 3117
2015
Q1 		$1.66M Buy
+26,728
New +$1.48M ﹤0.01% 2164

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

D.E. Shaw & Co's RARE Position: Q1 2026 in Review

D.E. Shaw & Co increased its Ultragenyx Pharmaceutical (RARE) stake by 266% in Q1 2026, buying an estimated $20.6M and bringing the position to 1,261,018 shares worth $26.4M. The position accounts for 0.02% of the portfolio, ranked #983.

D.E. Shaw & Co first reported a position in RARE in Q1 2015 and has held it in 36 quarters since. The position peaked at $99M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • D.E. Shaw & Co held 1,261,018 shares of Ultragenyx Pharmaceutical worth $26.4M as of Q1 2026.
  • D.E. Shaw & Co bought 916,255 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $20.6M.
  • Ultragenyx Pharmaceutical made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #983 holding.
  • D.E. Shaw & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 36 quarters since.
  • D.E. Shaw & Co's Ultragenyx Pharmaceutical position peaked at $99M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.